Egrifta (eh-GRIF-tuh, tesamorelin), the first drug to treat abdominal fat deposits caused by HIV meds

February 2011

You'll hear about Egrifta (eh-GRIF-tuh, tesamorelin), the first drug to treat abdominal fat deposits caused by HIV meds.

This lipodystrophy can be distressing to patients...decrease adherence to HIV meds...and might increase cardiovascular risk.

Egrifta is a human growth hormone releasing factor that's injected subcutaneously once daily.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote